SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive voluntary intellectual property licensing: considerations, requirements, and opportunities
10 references·0 citing·43 second hop
Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive voluntary intellectual property licensing: considerations, requirements, and opportunities (2022)Expanding access to biotherapeutics in lo…Global drug diffusion and innovation with the medicines patent pool (2022)Global drug diffusion and inn…Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forward (2022)Cancer medicines on the WHO M…Essential medicines for universal health coverage (2016)Essential medicines for unive…Cost–effectiveness thresholds: pros and cons (2016)Cost–effectiveness thresholds…The economics of biosimilars. (2013)The economics of biosimilars.Access to cancer medications in low- and middle-income countries (2013)Access to cancer medications …The logical underpinnings and benefits of pooled pharmaceutical procurement: A pragmatic role for our public institutions? (2012)The logical underpinnings and…A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries (2011)A win-win solution?: A critic…Developing Drugs For Developing Countries (2006)Developing Drugs For Developi…Patent pooling: Uncorking a technology transfer bottleneck and creating value in the biomedical research field (2003)Patent pooling: Uncorking a t…Abnormal economics in the health sector (1995)Powerful medicines: the benefits, risks, and costs of prescription drugs (2005)Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases (2009)A systematic review of pooled procurement of medicines and vaccines: identifying elements of success (2022)Projections of Global Mortality and Burden of Disease from 2002 to 2030 (2006)How to improve R&D productivity: the pharmaceutical industry's grand challenge (2010)Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment (2016)Systematic review and meta-analysis (2019)Financial Protection in Health among the Elderly – A Global Stocktake (2021)A Contribution to the Theory of Taxation (1927)Household catastrophic health expenditure: a multicountry analysis (2003)Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis (2008)Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? (2014)Innovative Approaches to Increase Access to Medicines in Developing Countries (2017)Payers’ experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia (2017)Pharmaceuticals and the Developing World (2002)The price of innovation: new estimates of drug development costs (2003)Do Scientists Pay to Be Scientists? (2004)Patents and the Global Diffusion of New Drugs (2015)Economics of the Pharmaceutical Industry (2018)Why miltefosine—a life-saving drug for leishmaniasis—is unavailable to people who need it the most (2018)Cochrane Handbook for Systematic Reviews of Interventions (2008)Cochrane Handbook for Systematic Reviews of Interventions (2010)Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending (2017)The path to longer and healthier lives for all Africans by 2030: the Lancet Commission on the future of health in sub-Saharan Africa (2017)Health systems development in Thailand: a solid platform for successful implementation of universal health coverage (2018)Global health 2035: a world converging within a generation (2013)Thresholds for the cost–effectiveness of interventions: alternative approaches (2014)Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold (2015)Cost-Effectiveness Thresholds: the Past, the Present and the Future (2018)An Introduction to the Main Types of Economic Evaluations Used for Informing Priority Setting and Resource Allocation in Healthcare: Key Features, Uses, and Limitations (2021)Quantifying the global burden of mental disorders and their economic value (2022)Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry (2004)Robust Inference With Multiway Clustering (2011)Environmental Regulations, Air and Water Pollution, and Infant Mortality in India (2014)Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received (2016)A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics (2018)Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey (2021)Towards Patent Pools in Biotechnology? (2006)Patent Pools and the Dynamic Incentives to R&D (2007)Technology Pooling Licensing Agreements: Promoting Patent Access Through Collaborative IP Mechanisms (2010)Orphan Drugs and Their Impact on Pharmaceutical Development (2018)Strategies to achieve fairer prices for generic and biosimilar medicines (2020)
this work references cited by second hop

References

  • 2016Cost–effectiveness thresholds: pros and cons789 cited
  • 2016Essential medicines for universal health coverage661 cited
  • 2013The economics of biosimilars.225 cited
  • 2006Developing Drugs For Developing Countries198 cited
  • 2011A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries138 cited
  • 2013Access to cancer medications in low- and middle-income countries99 cited
  • 2012The logical underpinnings and benefits of pooled pharmaceutical procurement: A pragmatic role for our public institutions?87 cited
  • 2022Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forward76 cited
  • 2022Global drug diffusion and innovation with the medicines patent pool71 cited
  • 2003Patent pooling: Uncorking a technology transfer bottleneck and creating value in the biomedical research field23 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work